Seller record · Telehealth service

NuuVim

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S5, analytical documentation: No certificate of analysis or lot document is published on the home page, the pricing page, the answers page, the terms or the telehealth disclosures. 1 more criterion also fails; see the table below.

At a glance

NuuVimTelehealth service

6/8criteria passed

Price: Semaglutide $79 a month introductory, then $133 standard; tirzepatide $133 introductory, then $199.67
Sells: compounded semaglutide injectable, compounded tirzepatide injectable, and 4 more
FDA letters: None on file

Visit NuuVim See all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A Texas telehealth weight-loss service selling compounded semaglutide and tirzepatide as weekly injections or daily oral liquids, plus Ozempic and Zepbound, billed in 3-month payments. Care comes from an affiliated physician group, its terms name Hallandale Pharmacy and VialsRX, and it prints no business address.

Operating entity NuuVim LLC

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	NuuVim's FAQ; NuuVim's telehealth prescription medication disclosures page
S2	Prescription gating	PASS	NuuVim's FAQ; NuuVim's website; NuuVim's telehealth prescription medication disclosures page
S3	Pharmacy identification	PASS	NuuVim's terms of service page; NuuVim's telehealth prescription medication disclosures page
S4	Compounding disclosure	PASS	NuuVim's website; NuuVim's pricing page; NuuVim's telehealth prescription medication disclosures page
S5	Analytical documentation	FAIL	NuuVim's pricing page; NuuVim's FAQ; NuuVim's terms of service page
S6	Business address	FAIL	NuuVim's contact page; NuuVim's terms of service page; NuuVim's privacy policy; NuuVim's HIPAA compliance page
S7	Price disclosure	PASS	NuuVim's pricing page; NuuVim's website
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed medical professional reviews each intake questionnaire and prescribes only if approved, and the telehealth disclosures say prescription decisions are made by independent licensed practitioners through Beluga Health, P.A.Source: NuuVim's FAQ; NuuVim's telehealth prescription medication disclosures page.

S2PASSThe answers page says the program starts with an intake, a short medical questionnaire, which a licensed medical professional reviews before prescribing, and the home page lists a quick online evaluation as the first step. The disclosures say payment does not guarantee approval for treatment.Source: NuuVim's FAQ; NuuVim's website; NuuVim's telehealth prescription medication disclosures page.

S3PASSThe terms name two partner pharmacies, Hallandale Pharmacy at 2666 SW 36th St, Fort Lauderdale, FL 33312 and VialsRX at 6220 Westpark Dr, Houston, TX 77057, and the telehealth disclosures name VialsRX as the dispensing pharmacy.Source: NuuVim's terms of service page; NuuVim's telehealth prescription medication disclosures page.

S4PASSEach compounded product is labeled compounded on the home page, where a note states that compounded medications have not been evaluated or approved by the FDA, and the pricing page and the telehealth disclosures say the same.Source: NuuVim's website; NuuVim's pricing page; NuuVim's telehealth prescription medication disclosures page.

S5FAILNo certificate of analysis or lot document is published on the home page, the pricing page, the answers page, the terms or the telehealth disclosures.Source: NuuVim's pricing page; NuuVim's FAQ; NuuVim's terms of service page.

S6FAILNo business address is printed. The contact page gives only an email address, and the only postal address in the terms is the copyright agent's, in care of ZenBusiness Inc. in Austin, Texas. The privacy policy, the HIPAA statement and the telehealth disclosures print none.Source: NuuVim's contact page; NuuVim's terms of service page; NuuVim's privacy policy; NuuVim's HIPAA compliance page.

S7PASSCompounded semaglutide injection at an introductory $79 a month for a buyer new to GLP-1 treatment, billed as $237 for the first 3 months, then $133 a month at the standard rate, billed as $399 every 3 months. Compounded tirzepatide injection at an introductory $133 a month, billed as $399 for the first 3 months, then $199.67 a month at the standard rate, billed as $599. The home page lists oral semaglutide from $79 and oral tirzepatide from $133 a month for new users, Ozempic from $1,498 a month and Zepbound from $1,892 a month.Source: NuuVim's pricing page; NuuVim's website.

S8PASSNo FDA warning letter names NuuVim or NuuVim LLC, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide injectable, compounded tirzepatide injectable, compounded semaglutide oral, compounded tirzepatide oral, Ozempic, Zepbound.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Visit NuuVim

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.